Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Whitehawk Therapeutics GAAP EPS of -$0.23 misses by $0.01 (SeekingAlpha) +++ WHITEHAWK THERAPEUTICS Aktie -3,55%

WHITEHAWK THERAPEUTICS Aktie

 >Aktienkurs 
2.78 EUR    (TradegateBSX)
Ask: 2.84 EUR / 1170 Stück
Bid: 2.72 EUR / 1220 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -3,8%
1 Monat: -12,5%
3 Monate: -31,5%
6 Monate: -22,7%
1 Jahr: +54,3%
laufendes Jahr: +32,7%
>WHITEHAWK THERAPEUTICS Aktie
Name:  WHITEHAWK THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00032Q1040 / A3CSR9
Symbol/ Ticker:  3350 (Frankfurt) / WHWK (NASDAQ)
Kürzel:  FRA:3350, ETR:3350, 3350:GR, NASDAQ:WHWK
Index:  -
Webseite:  https://ir.whitehawktx.co..
Profil:  Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing antibody-drug conjugate (ADC) cancer treatments. Its current portfolio centers on three ADC assets designed to target clinically validated proteins a..
>Volltext..
Marktkapitalisierung:  162.22 Mio. EUR
Unternehmenswert:  -5.43 Mio. EUR
Umsatz:  -
EBITDA:  -77.25 Mio. EUR
Nettogewinn:  -71.66 Mio. EUR
Gewinn je Aktie:  -1 EUR
Schulden:  -
Liquide Mittel:  76.51 Mio. EUR
Operativer Cashflow:  -62.25 Mio. EUR
Bargeldquote:  17.16
Umsatzwachstum:  -100%
Gewinnwachstum:  -690.39%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  WHITEHAWK THERAPEUTICS, WHITEHAWK THERAPEUTIC, AADI BIOSCIENCES
Letzte Datenerhebung:  09.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 57.01 Mio. St.
Frei handelbar: 57.64%
Leerverk. Aktien: 4.6%
Rückkaufquote: -48.41%
Mitarbeiter: 23
Umsatz/Mitarb.: 0.28 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 125.13%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 1.03
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -42.6%
Eigenkaprendite: -44.98%
>Peer Group
Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung
 
09.11.26 - 14:18
 Whitehawk Therapeutics GAAP EPS of -$0.23 misses by $0.01 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.11.26 - 14:03
 Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights (PR Newswire)
 
On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27 Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206 received Fast Track designation from the FDA Cash, cash equivalents and short-term......
01.10.26 - 14:03
 Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 (PR Newswire)
 
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most......
14.09.26 - 03:33
 Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 (PR Newswire)
 
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development......
10.09.26 - 22:06
 Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors (PR Newswire)
 
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced......
28.08.26 - 19:45
 What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? (Zacks)
 
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out....
26.08.26 - 17:30
 Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here′s What You Should Know (Zacks)
 
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
06.08.26 - 14:21
 Whitehawk Therapeutics GAAP EPS of -$0.20 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.07.26 - 13:09
 Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics (GlobeNewswire EN)
 
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities...
08.07.26 - 11:48
 Biocytogen and Whitehawk partner to develop ADCs (PBR)
 
Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC The post Biocytogen and Whitehawk partner to develop ADCs appeared first on Pharmaceutical Business review....
30.05.26 - 20:51
 Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 (PR Newswire)
 
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an......
28.05.26 - 22:06
 Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference (PR Newswire)
 
MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today......
21.05.26 - 23:09
 Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload (PR Newswire)
 
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007......
13.05.26 - 14:51
 Whitehawk Therapeutics secures $87.5M PIPE financing (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 14:30
 Whitehawk Therapeutics GAAP EPS of -$0.32 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.04.26 - 00:03
 Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 (PR Newswire)
 
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single‑digit mg/kg doses, with favorable tolerability (HNSTD 60......
18.04.26 - 00:01
 Insiderhandel: CHIEF FINANCIAL OFFICER verkauft Aktien von Whitehawk Therapeutics im Wert von 584808 USD (Insiderkauf)
 
Giacobello, Scott M. - Vorstand - Tag der Transaktion: 2026-04-16...
18.04.26 - 00:01
 Insiderhandel: CHIEF FINANCIAL OFFICER verkauft Aktien von Whitehawk Therapeutics im Wert von 297220 USD (Insiderkauf)
 
Giacobello, Scott M. - Vorstand - Tag der Transaktion: 2026-04-15...
16.04.26 - 22:06
 Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series (PR Newswire)
 
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today......
16.04.26 - 07:01
 Insiderhandel: Vorstand verkauft Aktien von Whitehawk Therapeutics im Wert von 336554 USD (Insiderkauf)
 
Ball, Bryan - Vorstand - Tag der Transaktion: 2026-04-14...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt Tage, da geht alles schief. Umso schöner ist es, wenn man weiß, daß man bedingungslos geliebt wird. - James Morgan
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!